



Addressing the Top 10 Clinical Challenges in **MELANOMA**

IN-PERSON + VIRTUAL
SATELLITE SYMPOSIUM

FRIDAY, JUNE 3, 2022

7:00 PM - 9:00 PM CDT

PROGRAM CHAIR

Jason J. Luke, MD, FACP

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Medical Crossfire®: Addressing the Top 10 Clinical Challenges in Melanoma**.

While the incidence of skin cancers continues to rise worldwide, significant advances in its management and the development of novel therapies have dramatically contributed to enhanced patient outcomes. In particular, the standard of care for patients with advanced melanoma has been, and continues to be, transformed by the ongoing accrual of data from clinical experience using targeted and immunologic therapies. It is critical that clinicians who treat these patients remain well-equipped with education, tools, and strategies that help them apply best practices. The Medical Crossfire® is one of PER®'s signature educational formats, and it features distinguished experts engaging in spirited discussions. In this activity, a panel of leading melanoma clinicians and clinical trialists explore the latest data regarding current and emerging therapeutic strategies for the management of melanoma across lines of care. The lively discussion will help place new developments into clinical context to help you optimize care for patients with melanoma.

In working together with PER®, we strive to make this activity, along with all of PER®'s accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with melanoma.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Jason J. Luke, MD, FACP

Director, Cancer Immunotherapeutics Center
Associate Professor of Medicine
University of Pittsburgh Hillman Cancer Center
University of Pittsburgh School of Medicine
Pittsburgh, PA

Phil Talamo, CHCP

President
Physicians' Education Resource®, LLC
Cranbury, NJ
ptalamo@gotoper.com

AGENDA

7:00 PM	Welcome, Introductions	Jason J. Luke, MD, FACP
7:05 PM	Selection of Patients for Combination Immunotherapy	Evan J. Lipson, MD
7:15 PM	Selection of Patients for BRAF/MEK and Immunotherapy Combinations	Yana G. Najjar, MD
7:25 PM	Selecting Appropriate Patients for Adjuvant Therapy in Melanoma	Sapna Patel, BA, MD
7:35 PM	Overcoming Resistance to Checkpoint Inhibition	Daniel Olson, MD
7:45 PM	Management of Treatment-Related Toxicities With Immunotherapy (irAEs)	Evan J. Lipson, MD
7:55 PM	Management of Treatment-Related Toxicities With BRAF/MEK and Immunotherapy Combinations	Yana G. Najjar, MD
8:05 PM	Clinical Use of Biomarkers in Advanced Melanoma	Jason J. Luke, MD, FACP
8:15 PM	Management Brain Metastases in Advanced Melanoma	Daniel Olson, MD
8:25 PM	Considerations in Trial Recruitment	Jason J. Luke, MD, FACP
8:35 PM	Emerging Approaches in Uveal Melanoma	Sapna Patel, BA, MD
8:40 PM	Post-Assessment Survey	Jason J. Luke, MD, FACP
8:45 PM	Question-and-Answer Session	Faculty Panel
8:55 PM	Closing Remarks	Jason J. Luke, MD, FACP
9:00 PM	Adjourn	

Upcoming PER® Conferences

2022

	6th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards		June 25
	21st Annual International Congress on the Future of Breast Cancer® East	New York City, NY	July 15-16
	6th Annual Live Medical Crossfire®: Hematologic Malignancies	New York City, NY	July 16
	23rd Annual International Lung Cancer Congress®	Huntington Beach, CA	July 28-30
	21st Annual International Congress on the Future of Breast Cancer® West	San Diego, CA	July 29-30
	6th Annual School of Nursing Oncology	San Diego, CA	July 29-30
	20th Annual School of Breast Oncology®	Atlanta, GA	November 3-5
	40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®	New York City, NY	November 9-11
	17th Annual New York Lung Cancers Symposium	New York City, NY	November 12
	7th Annual International Congress on Immunotherapies in Cancer™	New York City, NY	December 10

 Virtual Conference

 In-Person + Virtual Conference

Target Audience

This educational program is directed toward medical oncologists interested in the treatment and management of melanoma. Other health care professionals interested in the treatment and management of patients with melanoma will also be invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Assess recent clinical trial evidence concerning the safety and efficacy of immunotherapy used as single -agents or combination strategies for melanoma management
- Evaluate the efficacy and safety of targeted therapies, including BRAF/MEK inhibition, in the management of melanoma
- Describe treatment-related adverse events and appropriate management strategies for patients with melanoma
- Utilize approaches to optimize clinical decision-making across multiple lines of care in melanoma

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EDT on Monday, June 6, 2022. To access these materials, please visit <https://www.gotoper.com/melanoma0622iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://www.gotoper.com/melanoma0622iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until September 3, 2022.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Eisai Inc., Immunocore, Merck & Co. Inc., Novartis Pharmaceuticals Corporation.

Thank you for attending **Medical Crossfire®: Addressing the Top 10 Clinical Challenges in Melanoma**

To register for upcoming accredited CE live activities
or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future
PER® accredited CE activities.

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Shareholder	Other
Evan J. Lipson, MD	Bristol Myers Squibb, Merck, Sanofi Regeneron	Bristol Myers Squibb, Novartis, EMD Serono, Array BioPharma, MacroGenics, Merck, Sanofi Regeneron, Genentech, Odonate Therapeutics, OncoSec, Eisai, Natera, Instil Bio, Nektar, Pfizer, Rain Therapeutics			
Jason J. Luke, MD, FACP	To institution for clinical trials: AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Corvus, Day One, EMD Serono, F-Star, Genmab, Ikena, Immatix, Incyte, Kadmon, KAHN, MacroGenics, Merck, Moderna, Nektar, Next Cure, Numab, Palleon, Pfizer, Replimune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, Xencor	AbbVie, Bayer, Bristol-Myers Squibb, Castle, Checkmate, Codiak, Crown, Day One, Duke St, EMD Serono, Endeavor, Flame, Genentech, Gilead, Glenmark, HotSpot, Kadmon, Janssen, Ikena, Immunocore, Incyte, IO Biotech, MacroGenics, Merck, Nektar, Novartis, Partner, Pfizer, Regeneron, Roivant, Servier, Stingthera, Synlogic, SyntheKine			Data and safety monitoring board: AbbVie, Immutep, Evaxion. Advisory boards: 7 Hills, Bright Peak, Exo, F-Star, Inzen, RefleXion, Xilio (stock), Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavupharma, NeoTX, Onc.AI, OncoNano, Pyxis, STipe, Tempest
Yana G. Najjar, MD	Merck, Pfizer, Bristol Myers Squibb		Pfizer		
Sapna Patel, BA, MD	Bristol Myers Squibb, Foghorn Therapeutics, IDEAYA, InxMed, LvGen, Novartis, Provectus Biopharmaceuticals, Seagen, Syntrix Biosystems, TriSalus Life Sciences	Delcath, Advance Knowledge in Healthcare, Cardinal Health, Immunocore, Novartis, TriSalus Life Sciences		Pfizer, Amgen, Merck	

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair



Jason J. Luke, MD, FACP

Director of the Cancer Immunotherapeutics Center
Associate Professor of Medicine
University of Pittsburgh Medical Center Hillman Cancer Center
University of Pittsburgh School of Medicine
Pittsburgh, PA

Dr Luke is the director of the Cancer Immunotherapeutics Center and associate professor of Medicine at University Pittsburgh Medical Center. Dr Luke's translational research is focused on application of large-scale informatics to advance cancer immunotherapy. He has been a lead investigator for clinical trials of numerous novel immunotherapeutic agents. Dr Luke has received research support and/or professional awards from the National Cancer Institute, the US Department of Defense, the American Society of Clinical Oncology, and multiple professional or private societies. He received his medical degree from the Rosalind Franklin University of Medicine and Science in North Chicago, Illinois; he then trained at Boston University Medical Center in Massachusetts and Memorial-Sloan-Kettering Cancer Center in New York, New York. He subsequently held faculty positions at Dana-Farber Cancer Institute in Boston and the University of Chicago in Illinois.

Faculty



Evan J. Lipson, MD

Associate Professor, Medical Oncology
Melanoma and Cancer Immunology Programs
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, MD

Dr Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York, New York, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital and completed a medical oncology fellowship at the Johns Hopkins Kimmel Cancer Center.

Dr Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he evaluates novel therapies for patients with high-risk or advanced disease. He published the first reports of organ transplant recipients treated with immune checkpoint inhibitors (ICIs) for advanced cancer and the first description of kidney retransplantation performed after immunotherapy-related organ rejection. He initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers; patients are being recruited at several academic cancer centers across the United States.

Dr Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He is the principal investigator of a phase 2 trial testing ICI therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma; the first phase 3 study established the LAG-3 pathway as the third immune checkpoint pathway for which blockade has clinical benefit. He conducts regular clinical practices in Baltimore, Maryland, and at Sibley Memorial Hospital in Washington, DC, as part of the multidisciplinary melanoma program at Johns Hopkins.

**Yana G. Najjar, MD**

Assistant Professor of Medicine
Director, Clinical and Translational Research Center
University of Pittsburgh Medical Center Hillman Cancer Center
University of Pittsburgh School of Medicine
Pittsburgh, PA

Dr Najjar is an assistant professor of Medicine and director of the Clinical and Translational Research Center at the University of Pittsburgh Medical Center Hillman Cancer Center. Dr Najjar is a physician-scientist specializing in the treatment of advanced melanoma and research involving cancer immunotherapy for solid tumors. Dr Najjar earned her medical degree from the American University in Beirut and completed a postdoctoral fellowship at the National Cancer Institute. She pursued residency training at the Cleveland Clinic and completed a fellowship in hematology-oncology at the University of Pittsburgh. Her research focuses on developing novel combinations to treat advanced melanoma and evaluating mechanisms of tumor environment remodeling to render it less hostile to the host immune system; this bench-to-bedside approach has resulted in several investigator-initiated trials. She is an active member of the Society for Immunotherapy of Cancer and the ECOG Melanoma Committee. She has received Translational Team Science Awards from the Melanoma Research Alliance and the US Department of Defense.

**Daniel Olson, MD**

Assistant Professor of Medicine (Hematology/Oncology)
University of Chicago Medicine
Chicago, IL


Dr Olson received his medical degree from Rush University Medical College in Chicago, Illinois; he completed his residency in internal medicine at the McGaw Medical Center of Northwestern University in Chicago and fellowships in hematology/oncology and clinical pharmacology/pharmacogenomics at the University of Chicago Pritzker School of Medicine. Dr Olson's research centers around improving the efficacy and safety of immunotherapy. This includes a research focus on investigator-sponsored trials targeting mechanisms of resistance to PD-1 antibody therapy. He also is interested in improving the management of immune-related adverse events (irAEs) through translational work characterizing irAE mechanisms. Dr Olson will work both in the melanoma program and the developmental therapeutics programs, where he will focus on trials targeting mechanisms of immunotherapy resistance and help to expand the use of cell therapy approaches in solid tumors.


Sapna Patel, BA, MD

Associate Professor
 Director, Uveal Melanoma Program
 Director, Melanoma Fellowship Program
 Director, Online Media
 Department of Melanoma Medical Oncology
 The University of Texas MD Anderson Cancer Center
 Houston, TX

Dr Patel is a medical oncologist and director of the uveal melanoma program, online media, and fellowship program for melanoma medical oncology at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas. She received her medical degree from the University of Texas Medical Branch, Galveston, and had postgraduate training at the University of Colorado Health Sciences Center in Denver and the MDACC. She has led several investigator-initiated and multi-institutional clinical trials, including studies of targeted therapy, immunotherapy, T-cell therapy, and antibody-drug conjugates for uveal melanoma. Her laboratory work focuses on translational research that characterizes longitudinal molecular signatures in tumor samples from patients receiving treatment. She has received intramural and extramural funding, including grants from the National Institute of Health and Cancer Prevention and Research Institute of Texas. Her goal is to develop effective therapies for metastatic disease and to identify biomarkers to predict minimal residual disease and response to treatment.

Experience
 the new
 goto**per**.com



Streamlining
 education
 for the busy
 clinician



ASCO Direct™

HIGHLIGHTS

2022 Official Annual Meeting Review

Learn from leading experts about important, potentially practice-changing data in oncology and hematology.

Dallas, TX
June 18

Charlotte, NC
July 9

Nashville, TN
July 9

New York, NY
July 23

VIRTUAL
OPTIONS
AVAILABLE

40% off registration! Use code **ADH22**



Scan with smartphone
to explore the series



**CELEBRATE THE 40TH ANNIVERSARY
OF CFS® LIVE IN NYC**

**40th Annual
CFS®**

Chemotherapy Foundation
SYMPOSIUM

Innovative Cancer Therapy for Tomorrow®

SAVE
THE
DATE!

NOVEMBER 9 – 11, 2022
New York Marriott Marquis • New York, NY
In-person + Virtual Conference

This activity
is approved
for AMA PRA
Category 1
Credit™.



100 EXPERT
FACULTY
MEMBERS



25 TUMOR
TYPES



3 DAYS



1 MEETING

35% off registration! Use code **CFS22BF**



Scan with smartphone or visit the link below
gotoper.com/cfs22

